Información:
Error:
ID
34394
Descripción
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms; ODM derived from: https://clinicaltrials.gov/show/NCT01309789
Link
https://clinicaltrials.gov/show/NCT01309789
Palabras clave
Versiones (1)
- 17/1/19 17/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
17 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789
Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789
- StudyEvent: Eligibility
Similar models
Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
boolean
ID.2
Item
measurable disease of at least 1.5 cm
boolean
ID.3
Item
ecog performance status less than or equal to 2
boolean
ID.4
Item
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
boolean
ID.5
Item
current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
boolean
ID.6
Item
history of another primary malignancy that has not been in remission for at least 3 years
boolean
ID.7
Item
left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
boolean
ID.8
Item
viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
boolean
ID.9
Item
known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
boolean